Author:
Bozkurt Sureyya,Uz Burak,Buyukasik Yahya,Bektas Ozlen,Inanc Ayten,Goker Hakan,Kansu Emin
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference43 articles.
1. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21:8652–67.
2. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzi F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 2003;88:260–7.
3. Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, Rozman C, Carbonell F, Anger B, Heimpel H, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome positive chronic granulocytic leukemia. Blood. 1988;72:294–8.
4. Kantarjian HM, Smith TL, McCreddie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patients characteristics and therapy with survival. Blood. 1985;66:1326–35.
5. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11:11–5.